• Rotigotine: Dopamine D2/D3 Receptor Agonist in PD Research

  2026-05-07

  Rotigotine is a high-affinity dopamine D2/D3 receptor agonist that enables translational research across Parkinson’s disease, depression, and related neuropsychiatric models. This article delivers actionable workflows, troubleshooting insights, and evidence-backed protocol parameters for maximizing reproducibility and data clarity in both in vitro and in vivo settings.

• Moesin as a Biomarker for Endothelial Injury in Sepsis: Insi

  2026-05-06

  Chen et al. (2021) establish moesin (MSN) as a novel biomarker of endothelial injury in sepsis, linking increased serum MSN to disease severity and endothelial dysfunction. Their translational approach integrates patient data, murine models, and in vitro mechanistic studies, providing foundational evidence for MSN’s potential in sepsis diagnosis and therapeutic monitoring.

• Acifran and GPCR Structural Biology: Transforming Lipid Meta

  2026-05-06

  Explore how Acifran, a selective HM74A/GPR109A and GPR109B agonist, advances lipid metabolism research through structural biology insights. This article delivers unique, application-driven guidance for assay design, protocol optimization, and translational strategies.

• HNF4A Hypermethylation by H. pylori Drives Gastric Cancer EM

  2026-05-05

  This study establishes that Helicobacter pylori infection silences the tumor suppressor gene HNF4A in gastric epithelial cells via promoter hypermethylation, disrupting epithelial polarity and triggering EMT signaling. These findings clarify a pivotal epigenetic mechanism in gastric tumorigenesis and inform demethylation-based strategies for cancer research.

• Pseudo-UTP: Pseudo-Modified Uridine Triphosphate for Robust

  2026-05-05

  Pseudo-UTP (pseudo-modified uridine triphosphate) is a chemically modified nucleotide enabling enhanced mRNA synthesis with improved stability, reduced immunogenicity, and increased translation efficiency. Its strategic incorporation is key for next-generation mRNA vaccine and gene therapy development.

• 7-Ethyl-10-hydroxycamptothecin: Mechanistic Insights & Assay

  2026-05-04

  Explore how 7-Ethyl-10-hydroxycamptothecin empowers advanced colon cancer research through dual topoisomerase I and FUBP1 pathway inhibition. This article provides actionable, mechanistically detailed guidance for robust assay design.

• Shufeng Xingbi Therapy Modulates Immune Balance in AR Rats

  2026-05-04

  This study demonstrates that Shufeng Xingbi Therapy (SFXBT) can restore Th1/Th2 immune balance and beneficially alter gut microbiota in a rat model of allergic rhinitis. The findings highlight integrative immunological mechanisms and provide a framework for future research into microbiome-immune system interactions in allergic disease.

• Nascent Cone Precursors Identified as Origins of Human Retin

  2026-05-03

  This study establishes that ATOH7+ nascent cone precursors are the earliest cell-of-origin for human retinoblastoma, using advanced retinal organoid models with RB1 inactivation. The work clarifies how RB1 loss drives abnormal proliferation and tumorigenesis, offering a refined framework for targeted therapeutic research.

• Wnt agonist 1 (BML-284): Precision Tool for Wnt Pathway Rese

  2026-05-02

  Wnt agonist 1 (BML-284) is a high-purity, small-molecule activator of the canonical Wnt signaling pathway, widely used in developmental biology and chemoresistance research. Its defined EC50 (~0.7 μM) and specificity for TCF-mediated β-catenin transcription enable robust, reproducible modulation of the pathway. APExBIO supplies this compound for advanced research workflows requiring validated Wnt activation.

• Novobiocin: Aminocoumarin Antibiotic for Advanced Assays

  2026-05-02

  Novobiocin’s dual action as an aminocoumarin antibiotic and Hsp90 inhibitor unlocks novel workflows for antiparasitic, antiviral, and antibacterial resistance research. This article distills recent evidence and expert protocols to help labs maximize Novobiocin’s impact across experimental models while ensuring reproducibility and safety.

• Rosiglitazone (Brl-49653): Precision PPARγ Activation in Adi

  2026-05-01

  Rosiglitazone (Brl-49653) enables researchers to dissect PPARγ-driven adipogenesis and insulin sensitivity with reproducible, high-fidelity workflows. Drawing on the latest SEMA3E research, this guide delivers actionable protocol enhancements and troubleshooting strategies that maximize data quality in metabolic disease models.

• Lopinavir Identified as MERS-CoV Inhibitor: Insights from FD

  2026-04-30

  de Wilde et al. conducted a systematic screen of FDA-approved compounds, discovering that lopinavir and three other drugs inhibit MERS-CoV replication at low-micromolar concentrations in cell culture. These findings highlight the potential for drug repurposing in emerging coronavirus outbreaks and provide a framework for cross-pathogen antiviral research.

• Bleomycin Sulfate in Pulmonary Fibrosis Research Workflows

  2026-04-30

  Bleomycin Sulfate (Blenoxane) enables reproducible DNA damage and fibrosis modeling, bridging classic oncology and cutting-edge lung research. This guide translates the latest mitochondrial-IRF3 findings and protocol optimizations into actionable workflow enhancements.

• Ceruletide (Caerulein) in Pancreatic Fibrosis: Protocols and

  2026-04-29

  Explore how Ceruletide (Caerulein) enables nuanced pancreatic fibrosis modeling and gastrointestinal physiology studies. Gain new insights into autophagy-driven mechanisms and advanced assay design for translational research.

• SU5416 (Semaxanib): Applied Angiogenesis Inhibition in Cance

  2026-04-29

  SU5416 (Semaxanib) is a selective VEGFR2 inhibitor that enables precise suppression of tumor angiogenesis and immune modulation in translational workflows. Drawing on recent HIF1α pathway insights and validated protocols, this guide empowers researchers to maximize reproducibility and overcome common barriers in cancer and vascular biology assays.

451 records 19/31 page Previous Next First page 上5页 1617181920 下5页 Last page